Meridian Venture Partners Boosts ANI Pharma Stake

Ticker: ANIP · Form: SC 13D/A · Filed: Mar 14, 2024 · CIK: 1023024

Ani Pharmaceuticals Inc SC 13D/A Filing Summary
FieldDetail
CompanyAni Pharmaceuticals Inc (ANIP)
Form TypeSC 13D/A
Filed DateMar 14, 2024
Risk Levelmedium
Pages6
Reading Time7 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 13D-filing, ownership-stake, pharmaceuticals

Related Tickers: ANPH

TL;DR

Meridian Venture Partners now owns 6.9% of ANI Pharma, filing an amended 13D.

AI Summary

Meridian Venture Partners II, L.P. and its affiliates, including Robert E. Brown, Jr., have amended their Schedule 13D filing for ANI Pharmaceuticals, Inc. as of March 14, 2024. They now report beneficial ownership of 2,444,500 shares of common stock, representing approximately 6.9% of the outstanding shares. This filing indicates a change in their holdings or intentions regarding ANI Pharmaceuticals.

Why It Matters

This filing signals a significant ownership stake by Meridian Venture Partners in ANI Pharmaceuticals, potentially influencing corporate strategy or future transactions.

Risk Assessment

Risk Level: medium — Changes in significant shareholder filings can indicate shifts in investment strategy or potential activism, which carries inherent market risk.

Key Numbers

  • 2,444,500 — Shares Owned (Beneficial ownership reported by Meridian Venture Partners II, L.P.)
  • 6.9% — Ownership Percentage (Represents the stake of Meridian Venture Partners II, L.P. in ANI Pharmaceuticals, Inc.)

Key Players & Entities

  • Meridian Venture Partners II, L.P. (company) — Reporting entity
  • Robert E. Brown, Jr. (person) — Affiliated individual
  • ANI Pharmaceuticals, Inc. (company) — Subject company
  • Robert A. Graham (person) — Contact person

FAQ

What was the previous ownership percentage reported by Meridian Venture Partners II, L.P. for ANI Pharmaceuticals, Inc.?

The filing does not explicitly state the previous ownership percentage, only that this is an amendment (Amendment No. 8) indicating a change.

What is the CUSIP number for ANI Pharmaceuticals, Inc. common stock?

The CUSIP number for ANI Pharmaceuticals, Inc. common stock is 00182C103.

What is the business address of ANI Pharmaceuticals, Inc.?

The business address of ANI Pharmaceuticals, Inc. is 210 Main Street West, Baudette, MN 56623.

Who is listed as a group member alongside Meridian Venture Partners II, CO. and Meridian Venture Partners II, L.P.?

Robert E. Brown, Jr. is listed as a group member.

What is the filing date of this SC 13D/A amendment?

The filing date of this SC 13D/A amendment is March 14, 2024.

Filing Stats: 1,707 words · 7 min read · ~6 pages · Grade level 6.9 · Accepted 2024-03-14 07:30:38

Key Financial Figures

  • $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o

Filing Documents

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of the undersigned knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. March 14, 2024 Meridian Venture Partners II GP, L.P. BY: Meridian Venture Partners II, Co. ITS: GENERAL PARTNER By: /s/ Robert E. Brown, Jr. Robert E. Brown, Jr., President March 14, 2024 Meridian Venture Partners II, L.P. BY: Meridian Venture Partners II GP, L.P. ITS: GENERAL PARTNER BY: Meridian Venture Partners II, Co. ITS: GENERAL PARTNER By: /s/ Robert E. Brown, Jr. Robert E. Brown, Jr., President March 14, 2024 Meridian Venture Partners II, Co. By: /s/ Robert E. Brown, Jr. Robert E. Brown, Jr., President March 14, 2024 ROBERT E. BROWN, JR. By: /s/ Robert E. Brown, Jr. Robert E. Brown, Jr.

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.